HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study
Colorectal cancer (CRC) is a major public health problem and one of leading cancer related death all over the world. One of the prognostic parameters that play a role in different types of cancer is HER2. However, the role of HER2 in CRC and its relation with clinicopathological features and surviva...
Gespeichert in:
| Veröffentlicht in: | Asian Pacific Journal of Cancer Prevention 2024-06, Vol.25 (6), p.2023-2032 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2032 |
|---|---|
| container_issue | 6 |
| container_start_page | 2023 |
| container_title | Asian Pacific Journal of Cancer Prevention |
| container_volume | 25 |
| creator | El-Deek, Heba E M Hafez, Moemen M A Sotouhy, Thanaa M M Mosad Zaki, Eman Eltyb, Hanan A Kamal, Fatma M M |
| description | Colorectal cancer (CRC) is a major public health problem and one of leading cancer related death all over the world. One of the prognostic parameters that play a role in different types of cancer is HER2. However, the role of HER2 in CRC and its relation with clinicopathological features and survival is conflicting. We hypothesize that HER2 has different patterns of expression in CRC which may affect the prognosis of patients.
We studied sixty specimens of colorectal carcinoma for HER2 immunohistochemistry and gene amplification and correlate it with clinicopathological features and patients` survival.
Our data showed that negative HER2 expression was statistically associated with female gender (P = 0.010) and low & intermediate tumor budding (P = 0.030). There was a statistically significant relation between HER2 IHC and HER2 FISH amplification (P=0.000). Although neither HER2 immunoexpression and FISH amplification showed significant relation with overall survival nor disease free survival, HER2 amplified CRCs tended to have a worse survival compared with negative CRCs (40 months versus 50 months). The presence of male gender, lymphovascular invasion, nodal metastasis and distant metastasis (P = 0.013, 0.006, 0.006 and 0.000 respectively) were significantly statistically associated with poor overall survival. The presence of tumor grade III and high tumor budding (P = 0.035 and 0.007 respectively) were significantly statistically associated with shorter disease free survival.
Our results showed that HER2 IHC 3+ staining is highly predictive of HER2 gene amplification in colorectal carcinomas. There is a tendency towards poorer prognosis in amplified HER2 CRC cases. |
| doi_str_mv | 10.31557/APJCP.2024.25.6.2023 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11382861</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>38918664</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2753-1fc34e5ce03cb2a3548bc36c7192bac799700c146b66c127a87553dda427bd363</originalsourceid><addsrcrecordid>eNpVUdFOwjAUbYxGEP0ETX9gc23XdsQHQxYEDIlENPGt6bqOzbCWtBuRv3eAGnw6596bc27uPQDcoigkiFJ-P1o8p4sQRzgOMQ3ZnpEz0McxZwFn-OP8hPfAlfefURTThNNL0CPJECWMxX3gp-NXHBjdwvHXxmnvK2ugNDlctm5bbeUaVgamdm2dVk1XpdIo7fbNptRwadumhLaA49Vu0zzAWV23xpaVb6wqdd2h2x3cJtroplJw2bT57hpcFHLt9c0PDsD70_gtnQbzl8ksHc0DhTklASoUiTVVOiIqw5LQOMkUYYqjIc6k4sMhjyKFYpYxphDmsruNkjyXMeZZThgZgMej76bNap0rbRon12Ljqlq6nbCyEv8npirFym4FQiTBCUOdAz06KGe9d7r4E6NIHGIQhxjEPgaBqWB7Rjrd3enmP9Xv38k3oYyGUg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>El-Deek, Heba E M ; Hafez, Moemen M A ; Sotouhy, Thanaa M M ; Mosad Zaki, Eman ; Eltyb, Hanan A ; Kamal, Fatma M M</creator><creatorcontrib>El-Deek, Heba E M ; Hafez, Moemen M A ; Sotouhy, Thanaa M M ; Mosad Zaki, Eman ; Eltyb, Hanan A ; Kamal, Fatma M M</creatorcontrib><description>Colorectal cancer (CRC) is a major public health problem and one of leading cancer related death all over the world. One of the prognostic parameters that play a role in different types of cancer is HER2. However, the role of HER2 in CRC and its relation with clinicopathological features and survival is conflicting. We hypothesize that HER2 has different patterns of expression in CRC which may affect the prognosis of patients.
We studied sixty specimens of colorectal carcinoma for HER2 immunohistochemistry and gene amplification and correlate it with clinicopathological features and patients` survival.
Our data showed that negative HER2 expression was statistically associated with female gender (P = 0.010) and low & intermediate tumor budding (P = 0.030). There was a statistically significant relation between HER2 IHC and HER2 FISH amplification (P=0.000). Although neither HER2 immunoexpression and FISH amplification showed significant relation with overall survival nor disease free survival, HER2 amplified CRCs tended to have a worse survival compared with negative CRCs (40 months versus 50 months). The presence of male gender, lymphovascular invasion, nodal metastasis and distant metastasis (P = 0.013, 0.006, 0.006 and 0.000 respectively) were significantly statistically associated with poor overall survival. The presence of tumor grade III and high tumor budding (P = 0.035 and 0.007 respectively) were significantly statistically associated with shorter disease free survival.
Our results showed that HER2 IHC 3+ staining is highly predictive of HER2 gene amplification in colorectal carcinomas. There is a tendency towards poorer prognosis in amplified HER2 CRC cases.</description><identifier>ISSN: 2476-762X</identifier><identifier>ISSN: 1513-7368</identifier><identifier>EISSN: 2476-762X</identifier><identifier>DOI: 10.31557/APJCP.2024.25.6.2023</identifier><identifier>PMID: 38918664</identifier><language>eng</language><publisher>Thailand: West Asia Organization for Cancer Prevention</publisher><subject>Adult ; Aged ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - metabolism ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Egypt - epidemiology ; Female ; Follow-Up Studies ; Gene Amplification ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - metabolism ; Survival Rate</subject><ispartof>Asian Pacific Journal of Cancer Prevention, 2024-06, Vol.25 (6), p.2023-2032</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11382861/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11382861/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38918664$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El-Deek, Heba E M</creatorcontrib><creatorcontrib>Hafez, Moemen M A</creatorcontrib><creatorcontrib>Sotouhy, Thanaa M M</creatorcontrib><creatorcontrib>Mosad Zaki, Eman</creatorcontrib><creatorcontrib>Eltyb, Hanan A</creatorcontrib><creatorcontrib>Kamal, Fatma M M</creatorcontrib><title>HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study</title><title>Asian Pacific Journal of Cancer Prevention</title><addtitle>Asian Pac J Cancer Prev</addtitle><description>Colorectal cancer (CRC) is a major public health problem and one of leading cancer related death all over the world. One of the prognostic parameters that play a role in different types of cancer is HER2. However, the role of HER2 in CRC and its relation with clinicopathological features and survival is conflicting. We hypothesize that HER2 has different patterns of expression in CRC which may affect the prognosis of patients.
We studied sixty specimens of colorectal carcinoma for HER2 immunohistochemistry and gene amplification and correlate it with clinicopathological features and patients` survival.
Our data showed that negative HER2 expression was statistically associated with female gender (P = 0.010) and low & intermediate tumor budding (P = 0.030). There was a statistically significant relation between HER2 IHC and HER2 FISH amplification (P=0.000). Although neither HER2 immunoexpression and FISH amplification showed significant relation with overall survival nor disease free survival, HER2 amplified CRCs tended to have a worse survival compared with negative CRCs (40 months versus 50 months). The presence of male gender, lymphovascular invasion, nodal metastasis and distant metastasis (P = 0.013, 0.006, 0.006 and 0.000 respectively) were significantly statistically associated with poor overall survival. The presence of tumor grade III and high tumor budding (P = 0.035 and 0.007 respectively) were significantly statistically associated with shorter disease free survival.
Our results showed that HER2 IHC 3+ staining is highly predictive of HER2 gene amplification in colorectal carcinomas. There is a tendency towards poorer prognosis in amplified HER2 CRC cases.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Egypt - epidemiology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Amplification</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Survival Rate</subject><issn>2476-762X</issn><issn>1513-7368</issn><issn>2476-762X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUdFOwjAUbYxGEP0ETX9gc23XdsQHQxYEDIlENPGt6bqOzbCWtBuRv3eAGnw6596bc27uPQDcoigkiFJ-P1o8p4sQRzgOMQ3ZnpEz0McxZwFn-OP8hPfAlfefURTThNNL0CPJECWMxX3gp-NXHBjdwvHXxmnvK2ugNDlctm5bbeUaVgamdm2dVk1XpdIo7fbNptRwadumhLaA49Vu0zzAWV23xpaVb6wqdd2h2x3cJtroplJw2bT57hpcFHLt9c0PDsD70_gtnQbzl8ksHc0DhTklASoUiTVVOiIqw5LQOMkUYYqjIc6k4sMhjyKFYpYxphDmsruNkjyXMeZZThgZgMej76bNap0rbRon12Ljqlq6nbCyEv8npirFym4FQiTBCUOdAz06KGe9d7r4E6NIHGIQhxjEPgaBqWB7Rjrd3enmP9Xv38k3oYyGUg</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>El-Deek, Heba E M</creator><creator>Hafez, Moemen M A</creator><creator>Sotouhy, Thanaa M M</creator><creator>Mosad Zaki, Eman</creator><creator>Eltyb, Hanan A</creator><creator>Kamal, Fatma M M</creator><general>West Asia Organization for Cancer Prevention</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20240601</creationdate><title>HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study</title><author>El-Deek, Heba E M ; Hafez, Moemen M A ; Sotouhy, Thanaa M M ; Mosad Zaki, Eman ; Eltyb, Hanan A ; Kamal, Fatma M M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2753-1fc34e5ce03cb2a3548bc36c7192bac799700c146b66c127a87553dda427bd363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Egypt - epidemiology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Amplification</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El-Deek, Heba E M</creatorcontrib><creatorcontrib>Hafez, Moemen M A</creatorcontrib><creatorcontrib>Sotouhy, Thanaa M M</creatorcontrib><creatorcontrib>Mosad Zaki, Eman</creatorcontrib><creatorcontrib>Eltyb, Hanan A</creatorcontrib><creatorcontrib>Kamal, Fatma M M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El-Deek, Heba E M</au><au>Hafez, Moemen M A</au><au>Sotouhy, Thanaa M M</au><au>Mosad Zaki, Eman</au><au>Eltyb, Hanan A</au><au>Kamal, Fatma M M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study</atitle><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle><addtitle>Asian Pac J Cancer Prev</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>25</volume><issue>6</issue><spage>2023</spage><epage>2032</epage><pages>2023-2032</pages><issn>2476-762X</issn><issn>1513-7368</issn><eissn>2476-762X</eissn><abstract>Colorectal cancer (CRC) is a major public health problem and one of leading cancer related death all over the world. One of the prognostic parameters that play a role in different types of cancer is HER2. However, the role of HER2 in CRC and its relation with clinicopathological features and survival is conflicting. We hypothesize that HER2 has different patterns of expression in CRC which may affect the prognosis of patients.
We studied sixty specimens of colorectal carcinoma for HER2 immunohistochemistry and gene amplification and correlate it with clinicopathological features and patients` survival.
Our data showed that negative HER2 expression was statistically associated with female gender (P = 0.010) and low & intermediate tumor budding (P = 0.030). There was a statistically significant relation between HER2 IHC and HER2 FISH amplification (P=0.000). Although neither HER2 immunoexpression and FISH amplification showed significant relation with overall survival nor disease free survival, HER2 amplified CRCs tended to have a worse survival compared with negative CRCs (40 months versus 50 months). The presence of male gender, lymphovascular invasion, nodal metastasis and distant metastasis (P = 0.013, 0.006, 0.006 and 0.000 respectively) were significantly statistically associated with poor overall survival. The presence of tumor grade III and high tumor budding (P = 0.035 and 0.007 respectively) were significantly statistically associated with shorter disease free survival.
Our results showed that HER2 IHC 3+ staining is highly predictive of HER2 gene amplification in colorectal carcinomas. There is a tendency towards poorer prognosis in amplified HER2 CRC cases.</abstract><cop>Thailand</cop><pub>West Asia Organization for Cancer Prevention</pub><pmid>38918664</pmid><doi>10.31557/APJCP.2024.25.6.2023</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2476-762X |
| ispartof | Asian Pacific Journal of Cancer Prevention, 2024-06, Vol.25 (6), p.2023-2032 |
| issn | 2476-762X 1513-7368 2476-762X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11382861 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free E- Journals |
| subjects | Adult Aged Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Colorectal Neoplasms - genetics Colorectal Neoplasms - metabolism Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Egypt - epidemiology Female Follow-Up Studies Gene Amplification Humans Immunohistochemistry In Situ Hybridization, Fluorescence Lymphatic Metastasis Male Middle Aged Neoplasm Staging Prognosis Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Survival Rate |
| title | HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T18%3A41%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HER2-neu%20Expression%20and%20Survival%20in%20Colorectal%20Cancer%20in%20the%20South%20of%20Egypt;%20Immunohistochemistry%20and%20Genetic%20Study&rft.jtitle=Asian%20Pacific%20Journal%20of%20Cancer%20Prevention&rft.au=El-Deek,%20Heba%20E%20M&rft.date=2024-06-01&rft.volume=25&rft.issue=6&rft.spage=2023&rft.epage=2032&rft.pages=2023-2032&rft.issn=2476-762X&rft.eissn=2476-762X&rft_id=info:doi/10.31557/APJCP.2024.25.6.2023&rft_dat=%3Cpubmed_cross%3E38918664%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/38918664&rfr_iscdi=true |